PEARL STUDY Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. 25th June 2022: Teva Pharmaceuticals Europe B.V. announced promising interim results from its Pan-European Real World study (PEARL),…
Category: migraine
EC marketing authorisation for Vydura for migraine
Pfizer Inc and Biohaven Pharmaceutical Holding Company Ltd announced on 27th April that the European Commission (EC) has granted marketing authorisation for VYDURA® (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks…
Teva launches pre-filled pen for anti-CGRP migraine therapy AJOVY®▼ (fremanezumab) in the UK
On 21st July 2020, Teva UK Limited announced that a pre-filled pen for AJOVY® (fremanezumab) injection is now available, which will give patients on AJOVY® added convenience and flexibility not previously available with the AJOVY® pre-filled syringe. Indicated for the prevention of migraine in adults who have at least 4 migraine days per month, AJOVY®…
Licence update for BOTOX® increases involvement of MDT
News of BOTOX® licence update
Fremanezumab – first anti-CGRP preventive therapy approved by NICE
Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY®▼ (fremanezumab)
Fremanezumab: Chronic and episodic migraine medication approved for use within NHS Scotland
Industry news from Teva Pharmaceuticals
Emgality® (galcanezumab) Receives European Commission Approval for the Prophylaxis of Migraine in Adults
New migraine treatment from Lilly receives approval from European Commission
Are there limitations of headache days used alone as a diagnostic tool?
Enrico Greppi Award at EHF Congress for study supported and funded by Allergan
Novartis data shows treatment with erenumab (AMG 334) cuts migraine days by half
Migraine news from Novartis – Phase III STRIVE study shows positive results
